From: The impact on renal function after long-term use of anticoagulants in atrial fibrillation patients
Variables | Warfarin group | DOAC group | p value | ASMD |
---|---|---|---|---|
N | 879 | 879 | ||
Gender (male) | 490 (55.7) | 502 (57.1) | 0.597 | 0.002 |
Mean age | 67 ± 10.6 | 67 ± 10.3 | 0.967 | 0.002 |
Medical history 1 | ||||
Type 2 DM | 160 (18.2) | 166 (18.9) | 0.759 | 0.002 |
Hypertension | 335 (38.1) | 334 (38.0) | 1.000 | 0.0002 |
Hyperlipidemia | 172 (19.6) | 181 (20.6) | 0.634 | 0.002 |
Heart failure | 109 (12.4) | 115 (13.1) | 0.721 | 0.002 |
Previous stroke | 38 (4.3) | 49 (5.6) | 0.272 | 0.006 |
Vascular disease | 19 (2.2) | 16 (1.8) | 0.733 | 0.002 |
Chronic kidney disease | ||||
Stage < 3 | 556 (63.3) | 550 (62.6) | 0.805 | 0.001 |
Stage ≥3 | 323 (36.7) | 329 (37.4) | 0.001 | |
CHA2DS2-VASc | 2.23 ± 1.34 | 2.29 ± 1.37 | 0.351 | 0.044 |
Medication | ||||
ACEI/ARB | 494 (56.2) | 476 (54.2) | 0.415 | 0.003 |
Spironolactone | 0 (0) | 0 (0) | – | – |
Renal function | ||||
The average serum Cr (mg/dL) | 1.08 ± 0.35 | 1.09 ± 0.35 | 0.912 | 0.029 |
Baseline eGFR (mL/min/1.73 m2) | 70.33 ± 24.21 | 70.54 ± 24.67 | 0.861 | 0.009 |
1-year eGFR (mL/min/1.73 m2) | 68.98 ± 23.57 | 69.56 ± 24.09 | 0.613 | 0.024 |
2-year eGFR (mL/min/1.73 m2) | 69.06 ± 26.46 | 68.60 ± 24.84 | 0.708 | 0.018 |
Renal outcomes | ||||
Acute kidney injury (%) | 78 (8.9) | 39 (4.4) | < 0.001 | 0.017 |
Renal failure requiring HD (%) | 2 (0.2) | 2 (0.2) | 1.000 | 0 |
Renal death (%) | 4 (0.5) | 3 (0.3) | 1.000 | 0.002 |